Office of Management and Budget
Print this document
Public Comment Regarding: FDA Policy on Use of Ozone-Depleting Substances in Medical Products
Date:
6/17/2002
Signer
Organization
David D. Doniger - Senior Attorney and Policy Director - NRDC Climate Center
Return to this article at:
/omb/oira/0910/comments/text/371.html
Print this document